This biological characteristic is observed in a variety of different cell lines, including human PCa (PC3 and DU145), human leukemia (Jurkat cells), human embryonic kidney (293 cells), human myelogenous leukemia (KBM-5), human non-small cell lung carcinoma (H1299), and human histiocytic lymphoma (U937), colon cancer (HCT116 and Caco2) and pancreatic cancer (PANC-28) [12], [13], [14], [15], [16], [17]; these findings suggest that natural pentacyclic triterpenic acids can be broad inhibitors of NF-κB activation. Here, NFKB1 is linked to leukemia.